Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
Published: Mar 10, 2021 By Kate Goodwin
Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine January 2024 Read the full article from Life Science Magazine here: Read More
Read MoreOutcome Capital Life Science Market Pulse March 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?